Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma
Doxorubicin is one of the most active of all antitumor agents but at currently used doses
toxicity is common. When small doses are administered on a weekly schedule, the toxicity of
the drug appears to be reduced.
Patients are stratified for non-therapy purposes into 2 groups; doxorubicin is given
intravenously (IV) every week on an outpatient basis. Patients are monitored carefully, and
weekly blood samples are taken to determine the effectiveness and safety of treatment.
Patients are evaluated for toxicity after one dose of the drug and weekly thereafter.
Patients are evaluated for response to the drug after 4 weeks and monthly thereafter.
Intervention Model: Parallel Assignment, Primary Purpose: Treatment
United States: Federal Government
|Bellevue Hosp / New York Univ Med Ctr||New York, New York 10016|
|Mem Sloan - Kettering Cancer Ctr||New York, New York 10021|
|Univ of Rochester Medical Center||Rochester, New York 14642|
|UCLA CARE Ctr||Los Angeles, California 90095|
|San Francisco AIDS Clinic / San Francisco Gen Hosp||San Francisco, California 941102859|
|George Washington Univ Med Ctr||Washington, District of Columbia 20037|
|Univ of Miami School of Medicine||Miami, Florida 331361013|
|Tulane Univ School of Medicine||New Orleans, Louisiana 70112|
|Beth Israel Deaconess - West Campus||Boston, Massachusetts 02215|
|SUNY / Erie County Med Ctr at Buffalo||Buffalo, New York 14215|
|Ohio State Univ Hosp Clinic||Columbus, Ohio 432101228|
|Charity Hosp / Tulane Univ Med School||New Orleans, Louisiana 70112|